Kamada Ltd. (NASDAQ:KMDA) Sees Large Decrease in Short Interest

Kamada Ltd. (NASDAQ:KMDA) was the target of a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 35,100 shares, a decrease of 78.9% from the February 13th total of 166,100 shares. Based on an average daily volume of 194,200 shares, the short-interest ratio is currently 0.2 days. Currently, 0.1% of the shares of the company are sold short.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Kamada in a research note on Thursday, March 6th.

Kamada Stock Up 3.2 %

Shares of NASDAQ:KMDA traded up $0.23 during trading on Wednesday, reaching $7.35. 130,555 shares of the company’s stock traded hands, compared to its average volume of 257,986. The firm has a market cap of $422.48 million, a PE ratio of 26.21, a P/E/G ratio of 0.97 and a beta of 0.97. The company has a 50-day simple moving average of $7.18 and a 200-day simple moving average of $6.19. Kamada has a fifty-two week low of $4.74 and a fifty-two week high of $9.15.

Kamada Dividend Announcement

The business also recently declared a dividend, which will be paid on Monday, April 7th. Investors of record on Monday, March 17th will be paid a $0.20 dividend. The ex-dividend date of this dividend is Monday, March 17th.

Hedge Funds Weigh In On Kamada

Large investors have recently added to or reduced their stakes in the stock. Plato Investment Management Ltd acquired a new position in shares of Kamada during the 3rd quarter worth about $117,000. Public Employees Retirement System of Ohio acquired a new position in shares of Kamada during the third quarter valued at approximately $77,000. JPMorgan Chase & Co. purchased a new position in shares of Kamada in the fourth quarter valued at approximately $67,000. Geode Capital Management LLC boosted its stake in shares of Kamada by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock worth $178,000 after acquiring an additional 1,549 shares during the last quarter. Finally, Aristides Capital LLC increased its position in shares of Kamada by 12.1% during the fourth quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock worth $387,000 after purchasing an additional 6,850 shares in the last quarter. 20.38% of the stock is currently owned by institutional investors and hedge funds.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.